Collaboration & License Revenue was Ptc Therapeutics’s largest product and service line in fiscal 2025, bringing in $998.36M of $1.73B (58%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration & License Revenue | — | $100.03M | $304.00K | $998.36M | ||||||
| Net Product Revenue | $535.23M | — | — | — | ||||||
| Translarna1 | — | $332.75M | $321.07M | $235.30M | ||||||
| Emflaza | — | $255.09M | $207.22M | $146.36M | ||||||
| Royalty Revenue | $113.52M | $168.86M | $203.86M | $244.22M | ||||||
| Sephience | — | — | — | $111.15M | ||||||
| Collaboration Revenue | $50.05M | — | — | — | ||||||
| All Other Products | — | $31.50M | $36.95M | $37.26M | ||||||
| Upstaza/Kebilidi | — | $18.84M | $16.91M | $56.63M | ||||||
| Collaboration & Grant Revenue | — | — | — | — | ||||||
| Manufacturing Revenue | — | $7.70M | $1.70M | — | ||||||
| Translarna | — | $23.07M | $18.81M | -$98.63M | ||||||
| Total | $698.80M | $937.84M | $806.82M | $1.73B |
Ptc Therapeutics brought in $1.73B from its eight product and service lines in fiscal 2025, the year ended December 31, 2025. Ptc Therapeutics regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $806.82M. Collaboration & License Revenue was the largest at $998.36M (57.7%), ahead of Royalty Revenue at $244.22M (14.1%) and Translarna1 at $235.30M (13.6%). The other four lines brought in $351.40M combined.
Compared with fiscal 2024, Collaboration & License Revenue grew fastest, up 328,306.9% to $998.36M, while Emflaza fell the most, down 29.4% to $146.36M.
Ptc Therapeutics began breaking out Collaboration & License Revenue in fiscal 2023, Translarna1 in fiscal 2023, Emflaza in fiscal 2023 and Sephience in fiscal 2025. Ptc Therapeutics stopped reporting Net Product Revenue ($535.23M in fiscal 2022), Collaboration Revenue ($50.05M in fiscal 2022) and Manufacturing Revenue ($1.70M in fiscal 2024) as separate lines. The total is net of Translarna, which took $98.63M off revenue in fiscal 2025.
Non-Us was Ptc Therapeutics’s largest region in fiscal 2019, bringing in $190.30M of $306.98M (62%).
| Geography | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Non-Us | $81.50M | $145.24M | $171.00M | $190.30M | |||
| United States | $1.21M | $49.16M | $92.00M | $116.68M | |||
| Us | — | — | — | — | |||
| Total | $82.71M | $194.39M | $263.00M | $306.98M |
Ptc Therapeutics brought in $306.98M from its two regions in fiscal 2019, the year ended December 31, 2019. That was up 16.7% from $263.00M in fiscal 2018. Non-Us was the largest at $190.30M (62.0%), ahead of United States at $116.68M (38.0%).
Compared with fiscal 2018, United States grew 26.8% to $116.68M and Non-Us grew 11.3% to $190.30M. From fiscal 2016 to 2019, combined revenue from these regions grew from $82.71M to $306.98M, a compound annual growth rate of 54.8%. Non-Us' share of the total fell from 98.5% to 62.0%.
Ptc Therapeutics (PTCT) reports its revenue by product and service and by geography. In fiscal 2025, Collaboration & License Revenue was its largest product and service line, bringing in $998.36M (57.7% of the total), followed by Royalty Revenue at $244.22M (14.1%).
Collaboration & License Revenue was Ptc Therapeutics' largest product and service line in fiscal 2025, bringing in $998.36M, or 57.7% of the $1.73B total across its eight product and service lines.
Non-Us was Ptc Therapeutics' largest region in fiscal 2019, bringing in $190.30M, or 62.0% of the $306.98M total across its two regions.
United States grew faster than Non-Us in fiscal 2019, up 26.8% from $92.00M to $116.68M. Non-Us grew 11.3% to $190.30M.
Every figure comes from Ptc Therapeutics' annual financial filings, as reported. Each line keeps the name Ptc Therapeutics gives it, and years follow its fiscal calendar.
Ptc Therapeutics' revenue by product and service goes back to fiscal 2016, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.